Literature DB >> 35813008

LI-RADS Classification and Outcomes of Hepatocellular Carcinoma Treated With Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation.

Yuji Tachibana1, Ryo Takaji2, Miyuki Maruno2, Koichi Honda3, Mizuki Endo4, Kazunari Murakami3, Yoshiki Asayama2.   

Abstract

AIM: The aim of this study was to clarify the usefulness of the Liver Imaging Reporting and Data System (LI-RADS) for predicting a patient's prognosis after transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (TACE-RFA) for hepatocellular carcinoma (HCC) of Barcelona-Clinic Liver Cancer (BCLC) stage 0 or A. PATIENTS AND METHODS: We retrospectively analyzed cases of patients with HCC who underwent TACE-RFA (Jan 2005 to Dec 2015). Nodules were categorized based on their LI-RADS v2018 core. The LI-RADS category was assigned to each nodule using dynamic contrast-enhanced computed tomography. LR-3, LR-4 and LR-5 nodules were extracted. The overall (OS) and recurrence-free (RFS) survival was assessed among patients with BCLC 0 and BCLC A disease.
RESULTS: Of the 64 nodules extracted, 22 were LR-3 or -4 (mean±standard deviation=14.8±6.7 mm) and 42 were LR-5 (17.1±6.9 mm). Regarding OS, there was no significant difference between those with LR-3 or -4 and LR-5 (p=0.278). In terms of RFS, there was a significant difference between those with LR-3 or -4 and those with LR-5 (p=0.03). In particular, patients with BCLC A with LR-5 nodules had significantly poorer RFS than those with LR-3 or -4 (p=0.016) nodules.
CONCLUSION: For patients with BCLC A, LR-3 or -4 nodules are associated with a better prognosis than LR-5 nodules. Copyright 2022, International Institute of Anticancer Research.

Entities:  

Keywords:  Barcelona-Clinic Liver Cancer stage; Hepatocellular carcinoma; Liver Imaging Reporting and Data System; radiofrequency ablation; transcatheter arterial chemoembolization

Year:  2022        PMID: 35813008      PMCID: PMC9254100          DOI: 10.21873/cdp.10130

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  29 in total

1.  Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection.

Authors:  K N Khan; H Yatsuhashi; K Yamasaki; M Yamasaki; O Inoue; M Koga; M Yano
Journal:  J Hepatol       Date:  2000-02       Impact factor: 25.083

2.  Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.

Authors:  Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama
Journal:  J Hepatol       Date:  2012-11-21       Impact factor: 25.083

3.  Volumetric quantitative histogram analysis using diffusion-weighted magnetic resonance imaging to differentiate HCC from other primary liver cancers.

Authors:  Sara Lewis; Steven Peti; Stefanie J Hectors; Michael King; Ally Rosen; Amita Kamath; Juan Putra; Swan Thung; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2019-03

4.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

5.  Simplified staging for hepatocellular carcinoma.

Authors:  Jean-Nicolas Vauthey; Gregory Y Lauwers; Nestor F Esnaola; Kim-Anh Do; Jacques Belghiti; Nadeem Mirza; Steven A Curley; Lee M Ellis; Jean-Marc Regimbeau; Asif Rashid; Karen R Cleary; David M Nagorney
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

6.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

Authors:  Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

7.  Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.

Authors:  Shinya Sahara; Nobuyuki Kawai; Morio Sato; Takami Tanaka; Akira Ikoma; Kouhei Nakata; Hiroki Sanda; Hiroki Minamiguchi; Motoki Nakai; Shintaro Shirai; Tetsuo Sonomura
Journal:  Cardiovasc Intervent Radiol       Date:  2012-02-23       Impact factor: 2.740

8.  CT prediction of histological grade of hypervascular hepatocellular carcinoma: utility of the portal phase.

Authors:  Akihiro Nishie; Kengo Yoshimitsu; Daisuke Okamoto; Tsuyoshi Tajima; Yoshiki Asayama; Kousei Ishigami; Daisuke Kakihara; Tomohiro Nakayama; Yukihisa Takayama; Ken Shirabe; Nobuhiro Fujita; Hiroshi Honda
Journal:  Jpn J Radiol       Date:  2012-10-17       Impact factor: 2.374

Review 9.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.

Authors:  Victoria Chernyak; Kathryn J Fowler; Aya Kamaya; Ania Z Kielar; Khaled M Elsayes; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Amit G Singal; An Tang; Claude B Sirlin
Journal:  Radiology       Date:  2018-09-25       Impact factor: 11.105

10.  Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.

Authors:  Masashi Hirooka; Atsushi Hiraoka; Hironori Ochi; Yoshiyasu Kisaka; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa
Journal:  AJR Am J Roentgenol       Date:  2018-02-07       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.